Combining radiotherapy and angiogenesis inhibitors: Clinical trial design
- Radiation Oncology Branch, NCI, Bethesda, MD (United States)
- Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON (Canada)
Radiotherapy (RT) plays a vital role in the multimodality treatment of cancer. Recent advances in RT have primarily involved improvements in dose delivery. Future improvements in tumor control and disease outcomes will likely involve the combination of RT with targeted therapies. Preclinical evaluations of angiogenesis inhibitors in combination with RT have yielded promising results with increased tumor 'cure.' It remains to be seen whether these improvements in tumor control in the laboratory will translate into improved outcomes in the clinic. Multiple differences between these agents and cytotoxic chemotherapy must be taken into account when designing clinical trials evaluating their effectiveness in combination with RT. We discuss important considerations for designing clinical trials of angiogenesis inhibitors with RT.
- OSTI ID:
- 20788261
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 64, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2005.03.065; PII: S0360-3016(05)00641-3; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: Preliminary report of a randomized trial
Bevacizumab, Oxaliplatin, and Capecitabine With Radiation Therapy in Rectal Cancer: Phase I Trial Results